Helius Medical Technologies, Inc.

Helius Medical Technologies, Inc. is currently considered overvalued and financially unhealthy, with a negative Return on Equity of -1169.69% and a year-to-date stock performance decline of -96.82%, significantly underperforming its peers and the S&P 500.

As of June 11, 2025, the market trend has shifted to bearish, supported by negative signals from the MACD, KST, and moving averages, despite a bullish monthly RSI.

Helius Medical Technologies, Inc. is a micro-cap medical technology company focused on neurological wellness, with recent net sales of $0 million and a net loss of $4 million. The company has a market cap of $0.16 million and operates within the Pharmaceuticals & Biotechnology industry.

As of Jun 18, Helius Medical Technologies, Inc. has a market capitalization of 0.16 million, with net sales of 0.43 million and a net profit of -13.07 million over the last four quarters. The company reported shareholder's funds of 1.06 million and total assets of 3.54 million as of Dec 24.